Neuroprotection is a worthwhile pursuit given the tremendous costs posed on society by neurologic disease. Numerous difficulties in translating experimental data to clinical use have plagued the field, as demonstrated by the list of therapies discarded from clinical trials. Physicians and scientists from around the world have reevaluated past problems and are looking forward to improvements in clinical investigations. Combining thrombolytics with neuroprotective strategies, including antiexcitotoxic agents, free radical scavengers, vascular protective agents, antiinflammatories, and hypothermia, shows great promise and a bright future for treating cerebrovascular disease.
|Original language||English (US)|
|Number of pages||14|
|Journal||American Journal of Neuroradiology|
|State||Published - Feb 1 2004|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Clinical Neurology